Skip to main content

Table 2 Endpoint measures and timings for the MD part

From: HORNBILL: a phase I/IIa trial examining the safety, tolerability and early response of BI 764524 in patients with diabetic retinopathy and diabetic macular ischaemia—rationale, study design and protocol

  1. ADA anti-drug antibody, BCVA best-corrected visual acuity, ECG electrocardiogram, IOP intraocular pressure, IVT intravitreal, OCTA optical coherence tomography angiography, PK pharmacokinetic, SD-OCT spectral-domain optical coherence tomography angiography